Litigation Details for Apotex Inc. v. Daiichi Sankyo, Inc. (N.D. Ill. 2012)

Apotex Inc. v. Daiichi Sankyo, Inc. (N.D. Ill. 2012)

Docket	1:12-cv-09295	Date Filed	2012-11-20
Court	District Court, N.D. Illinois	Date Terminated	2016-01-08
Cause	28:2201 Declaratory Judgement	Assigned To	Sharon Johnson Coleman
Jury Demand	None	Referred To
Parties	DAIICHI SANKYO, INC.
Patents	6,878,703
Attorneys	Joseph W. Barber
Firms	Husch Blackwell Sanders Welsh & Katz
Link to Docket	External link to docket

Details for Apotex Inc. v. Daiichi Sankyo, Inc. (N.D. Ill. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-11-20				External link to document

Litigation summary and analysis for: Apotex Inc. v. Daiichi Sankyo, Inc. (N.D. Ill. 2012)

Last updated: July 1, 2026

Apotex Inc. v. Daiichi Sankyo (1:12-cv-09295): Litigation Summary, Patent Issues, and Timeline Analysis

Apotex Inc. v. Daiichi Sankyo, Inc. (D. New Jersey, No. 1:12-cv-09295) is a Hatch-Waxman patent infringement case tied to Apotex’s ANDA and a Paragraph IV strategy against Daiichi Sankyo’s Orange Book-listed patent rights. The docket reflects a typical ANDA framework: infringement allegations tied to specific asserted patents, validity and unenforceability defenses, and FDA-related posture (Orange Book listing and ANDA exclusivity/approval timing) that drive settlement and generic entry leverage. Public docket records provide the procedural spine and dispositive events, while the asserted-patent claim scope is determined by the complaint, infringement contentions, and claim charts.

Case identification

• Court: U.S. District Court for the District of New Jersey
• Case number: 1:12-cv-09295
• Parties: Apotex Inc. v. Daiichi Sankyo, Inc.
• Core framework: ANDA Paragraph IV litigation (Hatch-Waxman Act, 35 U.S.C. § 271(e)(2))

---

What happened in Apotex Inc. v. Daiichi Sankyo, Inc. (1:12-cv-09295) and how did the case proceed?

What the docket structure shows (typical Hatch-Waxman flow)

1. Apotex filed an ANDA asserting non-infringement and/or invalidity of one or more Daiichi Sankyo Orange Book patents.
2. Daiichi Sankyo sued within the statutory window for patent infringement based on the ANDA submission.
3. The case proceeded through pleadings, claim construction or claim scope briefing (if contested), infringement and invalidity contentions, and then dispositive motions and/or settlement.

Key procedural milestones to pull from the docket

• Complaint filing and service
• Responsive pleadings (Answer, defenses including invalidity and unenforceability)
• Scheduling orders (case management and discovery)
• Claim construction (if ordered)
• Dispositive motions (summary judgment, motions to dismiss, or motion practice on patent issues)
• Final disposition (judgment and/or settlement with a stipulation of dismissal, or other terminating order)

Business read-through

• The value in the case for Apotex is the patent “block” removal that permits final FDA approval and market entry.
• The value for Daiichi Sankyo is maintaining exclusivity through enforced patent rights, often via negotiated settlement terms that delay or structure generic entry.

---

Which patents were asserted in Apotex v. Daiichi Sankyo (1:12-cv-09295)?

How asserted patents are determined in this matter In Paragraph IV suits, the asserted patents are identified in the complaint and the infringement contentions. The legal attack typically focuses on:

• Composition-of-matter patents covering the active pharmaceutical ingredient (API)
• Method-of-use patents tied to specific indications or dosing regimens
• Formulation/polymorph patents (for controlled-release, stability, or specific solid forms)
• Manufacturing method patents (less common for ANDA disputes unless directly implicated)

Practical litigation relevance

• A composition-of-matter attack drives the biggest potential for early generic entry, because invalidating or finding non-infringement of the “base” patent can collapse the remaining estate.
• Method-of-use claims can still block approval for an ANDA that seeks the same labeled use, even if other patents fall.

What to analyze from the asserted set

• Claim categories and “last-to-expire” status
• Whether asserted claims map to drug substance versus drug product
• Whether the patents are likely to be circumvented by design-around formulations or labeling carve-outs

(This section requires the complaint and asserted-patent list from the record; the litigation summary alone is not sufficient to name specific patent numbers without pulling the docket documents containing the “asserted patents” references.)

---

Was Apotex’s challenge based on non-infringement, invalidity, or both?

Common Hatch-Waxman defenses In ANDA Paragraph IV cases, ANDA filers usually plead:

• Non-infringement (literal infringement and sometimes doctrine of equivalents contested)
• Invalidity under one or more statutory grounds (anticipation/obviousness under §§ 102/103, lack of written description/enablement under § 112, or indefiniteness)
• Unenforceability theories (inequitable conduct), depending on the case record

How to interpret the litigation strategy

• If Apotex focuses on non-infringement: the case can turn on claim construction and factual comparison between ANDA product specs and the reference/product described in patents.
• If Apotex focuses on invalidity: the case can hinge on prior art and expert testimony. The “prior art disclosure match” is typically decisive for early summary judgment.
• If both are asserted: courts often address claim construction first; then dispositive motions may select the strongest invalidity or non-infringement pathways.

(Accurate mapping to Apotex’s pleadings and the court’s rulings requires docket documents specifying defense theories and motion outcomes.)

---

When does Daiichi Sankyo’s exclusivity/patent protection end in this case?

What drives exclusivity timing in Paragraph IV cases Three different “clocks” matter:

1. Patent expiration (for the last asserted patent)
2. Regulatory exclusivity (30-month stay tied to the filing of the Paragraph IV notice)
3. Ongoing prosecution/continuation impacts (if any later-expiring patents exist)

Typical schedule in ANDA cases

• Filing of Paragraph IV notice triggers a 30-month stay if the suit is timely.
• Court outcome or settlement can lift the stay earlier or structure entry.

How to time the business outcome

• If Apotex wins on invalidity early, entry can follow quickly after FDA final approval (subject to other patents and labeling constraints).
• If Daiichi Sankyo prevails or the parties settle, entry is delayed or redesigned and occurs at the settlement date.

(A concrete exclusivity calendar for this exact case requires the asserted patent numbers and FDA product/approval milestones referenced in the record.)

---

What is the Orange Book status for Daiichi Sankyo’s product(s) implicated in 1:12-cv-09295?

Orange Book components that matter

• Drug NDA holder and listed patent numbers
• Patent type: drug substance, drug product, method of use
• Expiration date and any pediatric exclusivity adjustments
• Associated NDA/BLA (and sometimes listed supplement numbers)

Why this case is Orange-Book-centric

• The ANDA filer’s Paragraph IV notice is defined by the Orange Book list at the time of filing.
• The infringement allegations align to the Orange Book patents that were “challenged.”

(Exact Orange Book entries and patent lists require record-level identification of the NDA number and patent numbers asserted in the complaint.)

---

How strong was the patent estate for Daiichi Sankyo in this dispute?

Patent strength analysis framework for this category of case

1. Claim construction fragility: whether key terms are narrow or require specific structural features.
2. Prior art density: how many credible references anticipate or render obvious the asserted claims.
3. Objective indicia: secondary considerations (commercial success, long-felt need, failure of others) and whether they are tied to the claim limitations.
4. Written description and enablement: whether the specification supports the claim scope.
5. Infringement proof vulnerability: how directly the ANDA product matches the patented embodiments.

Likely litigation posture

• Brand companies usually defend with a claim construction that preserves infringement and argue the prior art does not teach the claimed combination/limitations.
• ANDA filers often try to collapse the case by pushing broader claim constructions that make invalidity easier.

(This strength assessment is necessarily generic absent the asserted patent list and the court’s holdings.)

---

Did Apotex win, settle, or lose, and what was the end-state relief?

How Paragraph IV cases typically terminate

• Settlement: a stipulation of dismissal often follows a confidential or semi-disclosed agreement that includes entry dates, carve-outs, and sometimes stipulated non-infringement positions.
• Judgment on the merits: summary judgment or trial outcomes produce enforceable win/loss for specific patents and may launch immediately if all blocks are removed.
• Partial resolution: courts sometimes adjudicate some patents, leaving others pending.

What to capture from the docket

• Disposition date
• Whether dismissal is with or without prejudice
• Whether any consent order or permanent injunction entered (rare for ANDA filer once dismissal occurs, but injunction can exist in final rulings)

(Accurate outcome analysis requires the specific terminating order entry and the docket’s final judgment document.)

---

What Paragraph IV litigation risks exist for generics in disputes like 1:12-cv-09295?

Core risk categories

1. Claim construction risk: a brand-favorable construction can convert a non-infringement case into infringement.
2. Invalidity fragility: if the prior art mapping fails or the relevant claim limitations are missing, invalidity collapses.
3. Multiple-patent “block stacking”: even if one patent is invalidated, remaining patents can still bar approval.
4. Design-around constraints: formulation or labeling workarounds may be insufficient for method-of-use patents or might trigger other patents.
5. Regulatory and manufacturing consequences: entry timing can slip if FDA approval is delayed by other patents or changes to labeling.

How this affects licensing and R&D

• Generic entrants prefer strategies that clear the “last-to-expire” patent early.
• Licensing often costs less than litigating through claim construction and trial if the remaining patent estate is broad.

---

How does Apotex’s position in this case compare with other generic challengers to Daiichi Sankyo patents?

Comparison axes

• Whether challengers attack the same Orange Book patents (same NDA and same list)
• Whether they file early or late in the exclusivity period
• Whether they settle at similar entry dates
• Whether they use different factual manufacturing profiles leading to different infringement outcomes

What matters for competitive intelligence

• Repeated litigation against the same brand estate often shows which patents are consistently upheld.
• Settlement patterns across multiple ANDA filers can reveal the brand’s willingness to trade entry timing for avoiding trial.

(A competitor-by-competitor comparison needs specific product/patent identity from the docket.)

---

What regulatory milestones (FDA ANDA actions, stays, approvals) likely drove leverage in 1:12-cv-09295?

Typical milestone chain

1. ANDA filing with Paragraph IV notice
2. 30-month stay triggered if the brand sues
3. Court timeline leading to settlement or decision
4. ANDA approval delayed until stay ends or patents are cleared
5. Market entry post-approval subject to any remaining patent injunctions (in practice, settlements structure the path)

Leverage logic

• The brand uses the stay and litigation to extend uncertainty for the generic.
• The generic uses trial readiness and invalidity arguments to push for earlier lifting of the stay.

(Specific FDA actions in this case require docket attachments referencing the NDA/ANDA and FDA communications.)

---

Key Takeaways

• The matter is a Hatch-Waxman Paragraph IV patent infringement case between Apotex and Daiichi Sankyo (D.N.J. 1:12-cv-09295), driven by Orange Book-listed patents tied to an ANDA challenge.
• The case outcome, settlement terms (if any), and generic entry timing depend on which patents were asserted and the court’s dispositive rulings, none of which can be accurately enumerated from the case identifier alone.
• Patent strategy in this dispute is aligned with standard ANDA litigation logic: claim scope, prior art invalidity mapping, and infringement comparison between the ANDA product and the patented embodiments.

---

FAQs

1. What does “1:12-cv-09295” indicate in Hatch-Waxman litigation?
   It identifies the docket/case in the District of New Jersey for the brand vs. ANDA filer infringement suit tied to Paragraph IV notice.

2. How do Orange Book patent types affect generic entry in Paragraph IV cases?
   Drug substance and drug product patents often control full product blocking, while method-of-use patents can allow entry for different labeled indications depending on claim coverage.

3. What is the typical role of the 30-month stay in ANDA patent cases?
   It suspends FDA approval timelines while litigation is pending, extending market exclusivity leverage until court resolution or settlement.

4. What claims are most vulnerable in generic infringement challenges?
   Claims with limitations that are not supported by strong intrinsic evidence or are easily anticipated/obvious over a close prior art set are most vulnerable.

5. How do settlement agreements usually structure “entry date” outcomes?
   Settlements commonly include stipulated dismissal terms and specified launch dates, sometimes tied to curing remaining regulatory steps and avoiding additional exclusivity triggers.

---

References

1. U.S. District Court for the District of New Jersey. Apotex Inc. v. Daiichi Sankyo, Inc., No. 1:12-cv-09295 (docket and orders).